Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.
Managed Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.
Patient-reported outcomes are playing a growing role in cancer research and are poised to become an important part of regulatory review in drug development—and even routine clinical cancer care.
Expanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.
Drug shortages take a toll, especially on emergency department patients.
A large chunk of what insurers spend can be saved by improving medication adherence through medication therapy management done right.
FDA’s approval of the first generic version of Copaxone for treating patients with relapsing forms of multiple sclerosis has industry insiders contemplating the impact on the generics market as well as payer coverage strategies.
Critics charge that the practice of adverse tiering to deter costly patients is violating the Affordable Care Act's coverage mandate.
Controversy surrounds the 340B Drug Discount Program, and many industry leaders agree that the healthcare law plays a large part.
Health plans and providers play a critical role in maintaining U.S. vaccination rates and can help reverse the recent MMR vaccination-rate decline, a factor responsible for the recent re-emergence of measles.